Tazverik Receives Accelerated Approval for Follicular LymphomaThe United States Food and Drug Administration (US FDA) has approved Tazverik for use in relapsed or refractory (R/R) follicular lymphoma. Tazverik (tazemetostat) is for adults with a mutation in... By Editorial Team 2 min readBookmark for laterReactions 0 reactions Comments1 comments
FDA Approves Darzalex Faspro For Multiple MyelomaThe United States Food and Drug Administration (US FDA) has approved Darzalex Faspro for the treatment of newly diagnosed or relapsed/refractory multiple myeloma. Darzalex Faspro (a combination of the drugs... By Editorial Team 3 min readBookmark for laterReactions 0 reactions Comments0 comments
FDA Approves Ibrutinib plus Rituximab for Chronic Lymphocytic LeukemiaThe U.S. Food and Drug Administration (FDA) has granted approval to the Janssen Pharmaceutical Companies of Johnson & Johnson to expand the indications for Imbruvica (ibrutinib) to be used in... By Editorial Team 2 min readBookmark for laterReactions 0 reactions Comments1 comments
What to Know About Cancer and COVID-19 (Coronavirus)The spread of the novel coronavirus, COVID-19, has changed our daily lives. But people with a higher risk for illness from COVID-19 are wondering what they can do to stay... By Editorial Team 4 min readBookmark for laterReactions 0 reactions Comments1 comments
Take the Fatigue and Health Survey!The 2020 Fatigue and Health survey has now closed. Thank you for your interest! We are excited to share the results with you soon.Exhaustion, tiredness, weariness... fatigue. We know chronic... By Editorial Team 1 min readBookmark for laterReactions 0 reactions Comments2 comments
FDA Makes Way for Experimental Drugs to Fight COVID-19On March 19, the U.S. Food and Drug Administration (FDA) approved the testing of two drugs, chloroquine (hydroxychloroquine) and remdesivir, to treat people with COVID-19. The drugs have been given... By Editorial Team 3 min readBookmark for laterReactions 0 reactions Comments1 comments
COVID-19: Tips To Reduce Your RiskWith all of the news circulating about the novel (new) coronavirus, it can be easy to feel overwhelmed or anxious. This is especially true if you are immune-compromised due to... By Editorial Team 4 min readBookmark for laterReactions 0 reactions Comments2 comments
COVID-19: Basics for the Immune-CompromisedFor those living with chronic health conditions, current news about the coronavirus (COVID-19) can be anxiety-inducing. We have questions and concerns about how the virus is transmitted, how it can... By Editorial Team 5 min readBookmark for laterReactions 0 reactions Comments4 comments
FDA Approves Sarclisa® for Previously Treated Multiple MyelomaThe U.S. Food and Drug Administration (FDA) has granted approval to Sanofi-Aventis U.S. LLC for Sarclisa® (isatuximab-irfc), to be used in combination with pomalidomide and dexamethasone for the treatment of... By Editorial Team 3 min readBookmark for laterReactions 0 reactions Comments1 comments
The American Cancer Society Issues 2020 Report on CancerThe American Cancer Society (ACS) recently released its report, Cancer Statistics, 2020. The report found that the death rate from cancer in the US is dropping. Between 1991 and 2017... By Editorial Team 3 min readBookmark for laterReactions 0 reactions Comments1 comments
FDA Approves New Combination Therapy for Follicular Lymphoma and Marginal Zone LymphomaThe U.S. Food and Drug Administration (FDA) recently approved Revlimid® (lenalidomide) in combination with Rituxan® (rituximab) for the treatment of previously treated follicular lymphoma and marginal zone lymphoma. This combination... By Pamela Munnelly1 min readBookmark for laterReactions 0 reactions Comments2 comments
FDA Expands Venclexta Approval for Previously Untreated CLL and SLLThe U.S. Food and Drug Administration (FDA) has recently expanded the approval for Venclexta® (venetoclax). Venclexta is now approved for previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia... By Pamela Munnelly1 min readBookmark for laterReactions 0 reactions Comments1 comments
FDA Expands Approval of Tibsovo for Treatment of AML with IDH1 MutationThe U.S. Food and Drug Administration (FDA) has expanded the approval of Tibsovo® (ivosidenib), a targeted therapy, for newly diagnosed acute myeloid leukemia (AML) with an IDH1 mutation in people... By Pamela Munnelly1 min readBookmark for laterReactions 0 reactions Comments0 comments
Introducing Our New Accessibility FeatureYou may have noticed that we added a new accessibility feature to our website. This feature will allow community members to change the size, color, or contrast of the text... By Editorial Team 1 min readBookmark for laterReactions 0 reactions Comments1 comments
Elzonris Approved for BPDCN and Sprycel Approval ExpandedThe FDA has approved Elzonris (tagraxofusp-erzs), a targeted therapy, for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and children over age 2. This is the first... By Pamela Munnelly1 min readBookmark for laterReactions 0 reactions Comments0 comments
Research Shows Cancer Likely to Become More Deadly than Heart DiseaseHeart disease is the leading cause of death in Americans, but new research shows that cancer is likely to surpass heart disease as the number one killer in 2020, especially... By Emily Downward2 min readBookmark for laterReactions 0 reactions Comments0 comments
FDA Approves First Biosimilar to Rituxan & New Drug for AMLOn November 28, 2018, the U.S. Food and Drug Administration (FDA) approved two new products that affect the blood cancer community: Truxima (rituximab-abbs) and Xospata (gilteritinib). Truxima is approved to... By Emily Downward2 min readBookmark for laterReactions 0 reactions Comments0 comments
FDA Approves 2 New Treatments for AML in Older Adults & Patients with ComorbiditiesThe U.S. Food and Drug Administration (FDA) recently approved two new treatment options for certain people with acute myeloid leukemia (AML): Daurismo™ (glasdegib) and Venclexta® (venetoclax) in combination with other... By Emily Downward2 min readBookmark for laterReactions 0 reactions Comments0 comments
First FDA Approval for Newly Diagnosed Types of Peripheral T-Cell LymphomaThe U.S. Food and Drug Administration (FDA) has approved Adcetris® (brentuximab vedotin) in combination with chemotherapy for the treatment of some peripheral T-cell lymphomas (PTCL). The approval was made through... By Pamela Munnelly1 min readBookmark for laterReactions 0 reactions Comments3 comments
FDA Approves New Immunotherapy Combination for Multiple MyelomaThe U.S. Food and Drug Administration (FDA) recently approved Empliciti (elotuzumab) as part of a combination treatment to treat certain people with relapsed or refractory multiple myeloma (MM). Empliciti can... By Emily Downward2 min readBookmark for laterReactions 0 reactions Comments0 comments